Literature DB >> 20107801

DNA damage induced by the anthracycline cosmomycin D in DNA repair-deficient cells.

Helotonio Carvalho1, Leandro M Garrido, Renata L A Furlan, Gabriel Padilla, Mateus Agnoletto, Temenouga Guecheva, João A P Henriques, Jenifer Saffi, Carlos Frederico Martins Menck.   

Abstract

PURPOSE: Anthracyclines have been widely used as antitumor agents, playing a crucial role in the successful treatment of many types of cancer, despite some side effects related to cardiotoxicity. New anthracyclines have been designed and tested, but the first ones discovered, doxorubicin and daunorubicin, continue to be the drugs of choice. Despite their extensive use in chemotherapy, little is known about the DNA repair mechanisms involved in the removal of lesions caused by anthracyclines. The anthracycline cosmomycin D is the main product isolated from Streptomyces olindensis, characterized by a peculiar pattern of glycosylation with two trisaccharide rings attached to the A ring of the tetrahydrotetracene.
METHODS: We assessed the induction of apoptosis (Sub-G1) by cosmomycin D in nucleotide excision repair-deficient fibroblasts (XP-A and XP-C) as well as the levels of DNA damage (alkaline comet assay).
RESULTS: Treatment of XP-A and XP-C cells with cosmomycin D resulted in apoptosis in a time-dependent manner, with highest apoptosis levels observed 96 h after treatment. The effects of cosmomycin D were equivalent to those obtained with doxorubicin. The broad caspase inhibitor Z-VAD-FMK strongly inhibited apoptosis in these cells, and DNA damage induced by cosmomycin D was confirmed by alkaline comet assay.
CONCLUSIONS: Cosmomycin D induced time-dependent apoptosis in nucleotide excision repair-deficient fibroblasts. Despite similar apoptosis levels, cosmomycin D caused considerably lower levels of DNA damage compared to doxorubicin. This may be related to differences in structure between cosmomycin D and doxorubicin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20107801     DOI: 10.1007/s00280-010-1244-x

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  5 in total

Review 1.  Insights into the critical role of the PXR in preventing carcinogenesis and chemotherapeutic drug resistance.

Authors:  Xiaxia Niu; Ting Wu; Gege Li; Xinsheng Gu; Yanan Tian; Hongmei Cui
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

2.  Mycothiol Peroxidase Activity as a Part of the Self-Resistance Mechanisms against the Antitumor Antibiotic Cosmomycin D.

Authors:  Roger D Castillo Arteaga; Leandro M Garrido; Brandán Pedre; Irina Helmle; Harald Gross; Bertolt Gust; Gabriel Padilla
Journal:  Microbiol Spectr       Date:  2022-05-05

3.  Cytotoxicity and genotoxicity of coronaridine from Tabernaemontana catharinensis A.DC in a human laryngeal epithelial carcinoma cell line (Hep-2).

Authors:  Walace Fraga Rizo; Luis Eduardo Ferreira; Vanessa Colnaghi; Juliana Simões Martins; Leonardo Pereira Franchi; Catarina Satie Takahashi; Rene Oliveira Beleboni; Mozart Marins; Paulo Sérgio Pereira; Ana Lúcia Fachin
Journal:  Genet Mol Biol       Date:  2013-03-04       Impact factor: 1.771

4.  Genome Sequence of Streptomyces olindensis DAUFPE 5622, Producer of the Antitumoral Anthracycline Cosmomycin D.

Authors:  Juan D Rojas; Antonio Starcevic; Damir Baranas̆ić; Maria A Ferreira-Torres; Camilo A Contreras; Leandro M Garrido; Welington L Araújo; Robson F de Souza; Jurica Zucko; Daslav Hranueli; Paul F Long; John Cullum; Gabriel Padilla
Journal:  Genome Announc       Date:  2014-06-26

5.  Cardiotoxicity of anthracycline therapy: current perspectives.

Authors:  Mihaela Valcovici; Florina Andrica; Corina Serban; Simona Dragan
Journal:  Arch Med Sci       Date:  2016-04-12       Impact factor: 3.318

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.